

Tylowan 20 Injection

(Tylosin)

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Tylowan-20 Injection

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

Active Substance(s):

Tylosin (as Tartrate) 200 mg

3. PHARMACEUTICAL FORM

Solution for injection

4. CLINICAL PARTICULARS

4.1 Target Species

Cattle & Goat.

4.2 Indications for use, specifying the target species

For the treatment in cattle & goat of diseases involving organisms sensitive to tylosin, such as erysipelas (*Erysipelothrix rhusiopathiae*), and pneumonia (*Mycoplasma hyopneumoniae*).

4.3 Contraindications

Not to be used in animals known to be hypersensitive to the active ingredient.

4.4 Special Warnings for each target species

Not applicable.

4.5 Special Precautions For Use

i. Special precautions for use in animals

Not recommended for horses.

Official, national and regional antimicrobial policies should be taken into account when the product is used.

ii. Special precautions for the person administering the veterinary medicinal product to animals

Care should be taken to avoid accidental self-injection. If accidental self-injection occurs, seek medical attention immediately. In the event of accidental skin contact, wash thoroughly with soap and water. In case of accidental eye contact, flush the eyes with plenty of clean, running water. Wash hands after use. Tylosin may induce irritation. Macrolides, such as tylosin, may also cause hypersensitivity (allergy) following injection, inhalation, ingestion or contact with skin or eye. Hypersensitivity to tylosin may lead to cross reactions to other macrolides and vice versa. Allergic reactions to these substances may occasionally be serious and therefore direct contact should be avoided. If you develop symptoms following exposure, such as skin rash, you should seek medical advice and show the physician this warning. Swelling of the face, lips and eyes or difficulty in breathing are more serious symptoms and require urgent medical attention.

4.6 Adverse reactions (frequency and seriousness)

Tolerance studies and toxicity studies suggest that undesirable effects are unlikely. Occasionally swelling at the injection site may occur, but this effect is transient.

4.7 Use during pregnancy, lactation or lay

Reports of adverse reproductive effects have not been noted. Use with care in pregnant animals.

4.8 Interaction with other medicinal products and other forms of interaction

None known.

4.9 Amount(s) to be administered and administration route

0.5 ml /10 kg bodyweight, equivalent to 10 mg of tylosin per kg bodyweight, by deep intramuscular injection every 12 hours, up to a maximum of 6 injections.

Do not inject more than 5ml at a single injection site.

To ensure a correct dosage, bodyweight should be determined as accurately as possible to avoid under dosing.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary

Tolerance studies of up to 156% of the recommended dosage rate have been carried out with localised swelling at the injection site being the only adverse effect. The lowest recorded LD₅₀ for tylosin from other acute toxicity studies was 400mg/kg bodyweight (40 times the recommended dosage rate) by intravenous injection in mice.

4.11 Withdrawal period(s)

Cattle & Goat (meat & offal): 16 days.

5. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: Macrolide antibiotic

ATCvet code: QJ01FA90

Pharmacodynamic/ Pharmacokinetic properties

Tylosin Tartrate 200 injection is an antibiotic preparation for parenteral administration to goat. The active ingredient is Tylosin. Each ml of Tylosin Tartrate 200 contains 200 mg of the active ingredient. Tylosin is a macrolide antibiotic which acts by interfering with bacterial protein synthesis. It has a spectrum of activity and mode of action similar to that of erythromycin, being usually bacteriostatic and largely active against Gram-positive aerobes like *Erysipelothrix*. Macrolides are well absorbed and often concentrate within cells and macrophages thereby targeting intracellular pathogens including Mycoplasmas.

6. PHARMACEUTICAL PARTICULARS

6.1 Incompatibilities

None known.

6.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years

Shelf life after first opening the immediate packaging: 28 days.

6.3 Special precautions for storage

Store below 25°C & Protect from light.

Following withdrawal of the first dose use the product within 28 days. Discard unused material. Keep out of reach of children.

6.4 Nature and composition of immediate packaging

50ml amber glass vial, with a rubber stopper and aluminium flip off-seals.

100ml amber glass vial, with a rubber stopper and aluminium flip off-seals.

6.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products, if appropriate

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

- 7. MARKETING AUTHORISATION HOLDER**
Nawan Laboratories (Pvt.) Ltd.
Plots No. 136-138, Sector-15,
Korangi Industrial Area, Karachi-74900, Pakistan.
- 8. MARKETING AUTHORISATION NUMBER**
Reg. No.: 025356
- 9. DATE OF FIRST AUTHORISATION**
Date of Reg.: 09-05-2000
- 10. DATE OF REVISION OF TEXT**
20-06-2024

MANUFACTURED BY:

 **NAWAN** | 136, Sector 15, Korangi Industrial
LABORATORIES (PVT) LTD. Area, Karachi-74900, Pakistan.